Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Neurocrine Biosciences's 5-Year ROIIC % for the quarter that ended in Dec. 2025 was 5.23%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Neurocrine Biosciences's 5-Year ROIIC % or its related term are showing as below:
FRA:NB3's 5-Year ROIIC % is ranked better than 55.33% of 900
companies
in the Drug Manufacturers industry
Industry Median: 2.425
vs FRA:NB3: 5.23
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Neurocrine Biosciences 5-Year ROIIC % Related Terms
Neurocrine Biosciences 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Neurocrine Biosciences's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NB3 vs VTRS, ELAN, UTHR: 5-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences 5-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's 5-Year ROIIC % falls into.
Neurocrine Biosciences's 5-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( 368.8129235 (Dec. 2025) - 269.205 (Dec. 2020) )
/
( 2418.186 (Dec. 2025) - 688.671 (Dec. 2020) )
=
99.6079235
/
1729.515
=
5.76%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Neurocrine Biosciences (FRA:NB3) has a 5-Year ROIIC % of 5.23 as of Dec. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Neurocrine Biosciences and its competitors. According to the industry distribution chart, Neurocrine Biosciences ranks #402 out of 900 companies in the Drug Manufacturers industry, placing it in the top 44.7%.
Is Neurocrine Biosciences' 5-Year ROIIC % too high?
Neurocrine Biosciences' current 5-Year ROIIC % is 5.23. The Drug Manufacturers industry median 5-Year ROIIC % is 2.43. Neurocrine Biosciences' value of 5.23 is 115.7% above this industry median. Based on the distribution chart, Neurocrine Biosciences ranks #402 out of 900 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Neurocrine Biosciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' 5-Year ROIIC % compare to VTRS and ELAN?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #402 out of 900 companies for 5-Year ROIIC %. This puts Neurocrine Biosciences in the upper half of its industry. The industry median 5-Year ROIIC % is 2.43. Neurocrine Biosciences' value of 5.23 is 115.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Drug Manufacturers company?
The median 5-Year ROIIC % among Drug Manufacturers companies is 2.43, based on 900 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurocrine Biosciences's current 5-Year ROIIC % of 5.23 is 115.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Neurocrine Biosciences and its competitors. For the Drug Manufacturers industry, the median 5-Year ROIIC % is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current 5-Year ROIIC % is 5.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Fairly Valued. The stock's GF Value™ is €163.09, compared to a current price of €147.95 — trading 9.3% below its estimated fair value. The current 5-Year ROIIC % is 5.23 and 115.7% above the Drug Manufacturers industry median of 2.43. Neurocrine Biosciences' overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current 5-Year ROIIC % is 5.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of €147.95 is trading 9.3% below its estimated GF Value™ of €163.09.
GuruFocus considers Neurocrine Biosciences to be Fairly Valued.
Key valuation signals for FRA:NB3:
5-Year ROIIC %: 5.23
GF Value™: €163.09 vs. price of €147.95 (9.3% below fair value)
Industry Position: 115.7% above the Drug Manufacturers median (#402 of 900)
No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
94GF Score
Get the complete analysis for FRA:NB3
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NB3 has been successfully added to your 
